Our findings are consistent with recent clinical studies showing that high stathmin level are correlated with poor response or resistance to paclitaxel containing chemotherapy in endometrial or breast cancer [28–30] or reversely that functional knockdown of stathmin using siRNA results in increased sensitivity to paclitaxel [9,31]. Here, STMN1 is linked to breast cancer.